Krystal Biotech, Inc. (NASDAQ:KRYS) is Hood River Capital Management LLC’s 9th Largest Position

Hood River Capital Management LLC increased its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 5.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 521,093 shares of the company’s stock after buying an additional 25,507 shares during the quarter. Krystal Biotech comprises about 2.0% of Hood River Capital Management LLC’s investment portfolio, making the stock its 9th biggest position. Hood River Capital Management LLC owned 1.82% of Krystal Biotech worth $95,694,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in KRYS. Dimensional Fund Advisors LP grew its stake in Krystal Biotech by 5.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 550,806 shares of the company’s stock worth $68,337,000 after buying an additional 30,169 shares during the period. Quest Partners LLC purchased a new stake in Krystal Biotech during the 4th quarter worth $127,000. Pier 88 Investment Partners LLC acquired a new stake in Krystal Biotech in the 4th quarter valued at $145,000. TD Asset Management Inc increased its holdings in Krystal Biotech by 82.7% in the 4th quarter. TD Asset Management Inc now owns 40,962 shares of the company’s stock valued at $5,082,000 after purchasing an additional 18,542 shares in the last quarter. Finally, Decheng Capital LLC purchased a new position in Krystal Biotech in the fourth quarter valued at about $8,160,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Stock Down 0.2 %

KRYS stock opened at $184.17 on Monday. Krystal Biotech, Inc. has a fifty-two week low of $93.95 and a fifty-two week high of $219.34. The stock has a market cap of $5.26 billion, a PE ratio of 98.49 and a beta of 0.82. The firm’s 50-day simple moving average is $195.14 and its 200 day simple moving average is $179.47.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, August 5th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.50 by $0.03. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The firm had revenue of $70.28 million for the quarter, compared to analysts’ expectations of $65.27 million. During the same period last year, the firm earned ($1.25) EPS. The firm’s revenue was up 70283900.0% compared to the same quarter last year. Equities analysts forecast that Krystal Biotech, Inc. will post 3.13 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the sale, the insider now directly owns 1,500,882 shares in the company, valued at $296,814,424.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 14.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on KRYS. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. HC Wainwright lifted their price objective on shares of Krystal Biotech from $200.00 to $221.00 and gave the company a “buy” rating in a research note on Wednesday, August 28th. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Stifel Nicolaus raised their price target on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Finally, Chardan Capital lifted their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Krystal Biotech presently has a consensus rating of “Buy” and an average price target of $196.75.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).